The correspondence surrounding the recent editorial on dosages of doxorubicin in Hodgkin lymphoma therapy invites critical discussion on the safety and efficacy of treatment protocols. Drs. Picardi and Vincenzi propose an increase in liposomal doxorubicin (Myocet™) dosage for young adults and adults with classic Hodgkin lymphoma, suggesting a adjusted regimen of Myocet combined with BVD, resulting in a total doxorubicin dose of 340 mg/m². Current guidelines indicate that doses exceeding 250 mg/m² are associated with significant cardiac risks, including subclinical and clinical heart dysfunction.
Despite favorable interim results, wherein a majority of patients exhibited PET negativity, the long-term cardiotoxic risks remain uncertain. Observations from follow-ups show no immediate cardiac decline; however, the potential for late-onset cardiomyopathy necessitates more in-depth investigation through future trials. Additionally, while Myocet is currently approved only in Europe for specific cancers, its application for patients with impaired cardiac function who cannot endure standard doses of doxorubicin could expand the therapeutic landscape.
This discourse is relevant to hematopoietic stem cell transplantation and bone marrow transplant settings, where understanding treatment-related complications, such as graft-versus-host disease and cardiotoxicity, is crucial for optimizing outcomes for both recipients and donors. Continued research into dosage modifications and patient safety remains imperative for advancing clinical practice and patient care in this domain.
Source: haematologica.org
